Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in...
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL as a treatment for pediatric eosinophilic esophagitis .


